Candesartan in Heart Failure assessment of reduction in Mortality and Morbidity (CHARM Alternative)

Study identifier:SH-AHS-0003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Candesartan in Heart Fail. assess. of reduction in Mortality & Morbidity. Candesartan in patients with Heart Failure who are ACE Inhibitor intolerant and have Depressed Left Ventricular Systolic Function

Medical condition

Congestive Heart Failure

Phase

Phase 3

Healthy volunteers

None

Study drug

Candesartan, Placebo

Sex

All

Actual Enrollment

6268

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Mar 1999

Primary Completion Date: 01 May 2003

Study Completion Date: 01 May 2003

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Active Comparator: 1	-
Placebo Comparator: 2	-

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1120&filename=CSR-SH-AHS-0003.pdf
Download
CSR-SH-AHS-0003.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Chris Granger